The increasing interest in successful weight management has resulted in considerable research into groundbreaking treatments. Currently, Retatrutide, a combined -action GIP and glucagon-like peptide-1 (GLP-1) receptor stimulator, has demonstrated promising results in patient trials, implying potential for considerable weight decrease. As a result ,